KalVista's rival to Takeda's Firazyr aces trial, sending stock up 200% Veru's COVID-19 drug hopeful scrapes efficacy hurdle, but questions remain Tmunity expands Penn pact, picking up another CAR-T program, rights to manufacturing tech Sponsored: Understanding the pharmaceutical lifecycle and the benefits of a menu-driven approach Drug Farm bags $56M to take novel hepatitis B drug into humans Deerfield, Dana-Farber team up again, this time on $130M translational science deal Verily links with Janssen for at-home COVID-19 immune system study Boosting the response to immuno-oncology in pancreatic cancer by targeting inflammation Cancer trials a major victim of pandemic as global studies dropped by 60%: JAMA Eli Lilly CFO steps down—and gives up $24M-plus in cash and equity—after investigation finds 'inappropriate' behavior Featured Story By Nick Paul Taylor KalVista Pharmaceuticals’ oral plasma kallikrein inhibitor has reduced the use of rescue medication in patients suffering swelling attacks associated with a rare disease. The phase 2 results boost KalVista’s prospects of establishing KVD900 as an alternative to injectable treatments such as Takeda’s Firazyr and Pharming’s Ruconest. read more |
| |
---|
| Top Stories By Ben Adams Little-known Miami biotech Veru saw its shares jump this week after reporting seemingly positive data from a small phase 2 in COVID-19 patients. read more By Amirah Al Idrus Tmunity Therapeutics was born out of an extensive collaboration with the University of Pennsylvania that netted it the technology, know-how and programs it needed to go after better cell therapies for cancer. Now, the biotech is bolstering that pact, picking up a new CAR-T program and the rights to certain technologies. read more Sponsored By: Avid Bioservices The concept of one-stop shopping has become more popular in the biopharmaceutical industry in recent years, prompting many traditional commercial manufacturing organizations (CMOs) to provide support to clients throughout the manufacturing lifecycle. read more By Nick Paul Taylor Drug Farm has raised $56 million to take its lead hepatitis B treatment into the clinic. The series A round will equip Drug Farm to start learning whether its mutagenesis-based approach to drug target discovery translates into effective therapies. read more By Amirah Al Idrus Deerfield Management and the Dana-Farber Cancer Institute are at it again. Two years after teaming up on protein degradation R&D, the duo inked a 10-year partnership aimed at turning scientific discoveries at Dana-Farber into new medicines and diagnostics for cancer. read more By Conor Hale Verily is teaming up with Johnson & Johnson’s Janssen division to observe the body’s earliest immune responses to a coronavirus infection, with people participating in the research from within their own homes. read more By Arlene Weintraub Immune-stimulating antibodies that target the receptor CD40 are emerging as promising therapies for pancreatic cancer, but they don't work in many patients. Penn researchers discovered that high levels of inflammation impede the response to CD40 drugs. Combinations that suppress inflammation may be the answer, they said. read more By Ben Adams Data out from Medidata and published by the JAMA network have found oncology tests dropped off dramatically in the first wave of the pandemic last year. read more By Eric Sagonowsky After Eli Lilly heard allegations of an inappropriate relationship between its chief financial officer, Josh Smiley, and an employee, the drugmaker hired an external firm to investigate. Now, Smiley is not only out of the job, but also forfeiting $24 million in cash and equity awards. read more Enrollment Showcase Sponsored by: University of Florida College of Pharmacy Learn about the Top 5-Ranked UF College of Pharmacy’s online graduate programs in pharmaceutical outcomes & policy. Select from five specializations, including the new pharmaceutical value assessment & communication option. Over half of graduates progress to a new role within one year. Register now. |
| |
---|
| Resources Sponsored By: Medidata, a Dassault Systèmes company 8 parameters to optimize your “Path to Virtualization” across site- and patient-centric capabilities in this Sponsor Edition eBook. Sponsored By: LabVantage Solutions Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem. Sponsored By: Acorn AI, a Medidata Company Acorn AI has developed a flexible and scalable Commercial Data Model that provides pharmaceutical companies with the data-driven insights required to respond to the industry’s ever-changing landscape. Download the whitepaper to learn how Acorn AI’s intuitive data model enables launch success and more. Sponsored By: Outer Edge Technology Criminals Are Actively Exploiting The CV-19 Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become A Cybercrime Statistic -- Make These Cost-Effective IT Changes Now! Sponsored by: Cytiva It’s an exciting time to pioneer what could be a life-changing medicine. Clear the path to the clinic with pro tips and expert insights from industry leaders. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Premier Research Browse the latest learnings and insights from our clinical development professionals. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Virtual Clinical Trials Summit February 9-10, 2021 | Virtual Event Learn what it takes to get a drug developed and approved February 23-24, 2021 | 12 p.m. EST / 9 a.m. PST For non-scientists. Learn the science driving biopharma. February 25-26, 2021 | 9 a.m. EST / 6 a.m. PST Learn what it takes to get a drug developed and approved March 9-10, 2021 | 9 a.m. EST / 6 a.m. PST Learn the science driving biopharma. Specific for the non-scientist. March 18-19, 2021 | 12 p.m. EST / 9 a.m. PST Learn what it takes to get a drug developed and approved April 13-14, 2021 | 12 p.m. EST / 9 a.m. PST
Learn the science driving biopharma. Specific for the non-scientist. April 20-21, 2021 | 12 p.m. EST / 9:00 a.m. PST Learn what it takes to get a drug developed and approved April 22-23, 2021 | 9:00 a.m. EST / 6 a.m. PST Learn the science driving biopharma. Specific for the non-scientist. May 6-7, 2021 | 9:00 a.m. EST / 6 a.m. PST Vaccines, cell and gene therapy, therapeutic antibodies and RNA drugs May 20-21, 2021 | 12 p.m. EST / 9 a.m. PST Learn what it takes to get a drug developed and approved June 2-3, 2021 | 9 a.m EST / 6 a.m.PST Vaccines, cell and gene therapy, antibodies, and RNA-based drugs June 10-11, 2021 | 9 a.m. EST / 6 a.m. PST Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. |